GSK - THE PAXIL FILES

SPECIAL THANKS TO DOUG BREMNER, CHRISTOPHER LANE AND HEALTHY SKEPTICISM FOR MAKING SOME OF THESE DOCUMENTS AVAILABLE

PAXIL/SEROXAT - GREATEST NUMBER OF SUICIDE ATTEMPTS


----

GSK PAXIL CASPPER DOCUMENT

----

GLAXOSMITHKLINE PROGRAM CALLED “PSYCHNET”

----

FOREWORD BY PAUL N. JENNER, DIRECTOR AND VICE PRESIDENT OF NEUROSCIENCE AND STRATEGIC PRODUCT DEVELOPMENT


----

SECTION 1: TOWARDS THE SECTION BILLION -- ALL SSRI'S ARE NOT THE SAME


----

SECTION 2: NEW INDICATIONS: SOCIAL ANXIETY DISORDER / SOCIAL PHOBIA


----

SECTION 3: ISSUES MANAGEMENT: MANAGING THE DISCONTINUATION ISSUE

----

"DURATION OF TREATMENT AND DEPRESSION: RELAPSE AND RECURRENCE RATES"

----

"PAXIL CR" PRODUCT MONOGRAPH


----

PAXIL LITIGATION DOCUMENTS


----

GSK's PAXIL.COM...STILL A WEALTH OF [DIS] INFORMATION


----

DOCUMENT RETENTION, LETTERS TO MINISTERS, LETTERS AND EMAILS ABOUT SEROXAT AND LIST OF FOI REQUESTS


----

MINUTES OF MEETING BETWEEN MHRA AND BOB FIDDAMAN


----

PRESS RELEASE: GSK INVESTIGATION CONCLUDES


----

MHRA INVESTIGATION INTO GLAXOSMITHKLINE/SEROXAT


----

GSK SEROXAT - LETTER TO GSK FROM MHRA


----

GSK SEROXAT - LETTER TO TRADE ASSOCIATIONS


----

SUMMARY OF REGULATORY ACTION


----

LETTER FROM GSK CHIEF MEDICAL OFFICER TO MHRA


----

MHRA RESPONSE TO LETTER FROM GSK CHIEF MEDICAL OFFICER


----

PAXIL STUDY 329 ALL OVER AGAIN?
Article By Bob Fiddaman


----

MARKET SENTINEL'S STAKEHOLDER ANALYSIS COMMISSIONED BY THE UK MHRA TO ASSESS PUBLIC DISCUSSION OF THE SEROXAT CONTROVERSY


----

KILKER V GLAXOSMITHKLINE COURT TRANSCRIPTS

----

PAXIL STUDY 329: PAROXETINE vs IMIPRAMINE vs PLACEBO IN ADOLESCENTS

Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING